Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the amelioration of the sleep architecture
of patients with schizophrenia and schizophrenia-related insomnia, treated with either 9 mg
of extended-release paliperidone ER or placebo, using polysomnography.
Phase:
Phase 2
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.